Navigant Acquires Dymedex Consulting to Expand Its Life Sciences Practice and Overall Capabilities in Medical Technology
September 01 2016 - 8:05AM
Business Wire
Data-driven market development methodologies and systems help
clients realize full potential of their products and
markets
Navigant (NYSE: NCI) today announced it acquired Dymedex
Consulting, LLC, a Minnesota-based firm that provides data-driven
market analysis to accelerate adoption and maximize growth for
medical device companies. Dymedex offers insights through global
strategic market assessments, tactical geography planning, and
market landscape analysis.
The addition of the experienced Dymedex team, as well as the
firm’s proprietary market development tools and methodologies,
expands Navigant’s capabilities in the medical technology and life
sciences industries. Navigant also plans to make the Dymedex tools,
methodologies and expertise available to its healthcare
clients.
“In today’s medical device market, it is critical that companies
create the conditions necessary to optimize growth, utilization,
and adoption. Dymedex has a proven methodology to assist companies
in accelerating the development of global markets,” said Eduardo
Schur, managing director and Global Life Sciences practice leader,
Navigant. “And while Dymedex has been successful in the medical
technology field, we are excited by the opportunity to expand their
methodologies into other life sciences areas such as
pharmaceuticals and biotech.”
The Dymedex team, including founders Joseph Galatowitsch and
Ross Meisner, will join the Navigant Life Sciences practice within
the company’s Healthcare segment.
“Uncovering critical market insights and facilitating
data-driven decisions is vital to the success of life science and
med tech companies,” said Joseph Galatowitsch, co-founder of
Dymedex Consulting and managing director at Navigant. “The
combination of Dymedex’s proprietary tools and methodologies with
Navigant’s deep industry expertise and global footprint will enable
our clients to fully capitalize on their opportunities.”
Based in Minneapolis, Dymedex has evaluated over 100 different
medical technologies for their clients and worked in nearly 20
countries around the world. With deep knowledge of the challenges
clients face, Dymedex helps clients address complex problems across
multiple therapeutic and clinical areas and works on a wide range
of medical technologies and business models, including monitoring
and diagnostic products, therapies of all types, surgical tools,
disposables, capital equipment, and other complex or combination
devices.
About Navigant
Navigant Consulting, Inc. (NYSE: NCI) is a specialized, global
professional services firm that helps clients take control of their
future. Navigant’s professionals apply deep industry knowledge,
substantive technical expertise, and an enterprising approach to
help clients build, manage and/or protect their business interests.
With a focus on markets and clients facing transformational change
and significant regulatory or legal pressures, the Firm primarily
serves clients in the healthcare, energy and financial services
industries. Across a range of advisory, consulting, outsourcing,
and technology/analytics services, Navigant’s practitioners bring
sharp insight that pinpoints opportunities and delivers powerful
results. More information about Navigant can be found at
navigant.com.
About Dymedex
Dymedex is a market development consulting firm that helps
medical technology companies reach full market potential by using
data-driven market analysis and insight to improve decision-making.
Dymedex has developed over 100 customized medical technology market
development plans in all major markets globally. Dymedex
understands the industry’s challenges, and relies on more than 80
years of combined experience that includes nearly every major
disease and condition. Data-driven critical thinking, shaped by
broad experience, helps us consistently deliver key insights. At
Dymedex, we are driven to provide foundational scientific market
analysis that organizations can rely on to move forward with
confidence.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160901005264/en/
Navigant Investor RelationsAaron Miles312.583.5820orNavigant
Corporate CommunicationsMegan Maupin312.583.5703
Navigant Consulting (NYSE:NCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navigant Consulting (NYSE:NCI)
Historical Stock Chart
From Apr 2023 to Apr 2024